About this trial
The WSO Brain and hEart globAl iniTiative - STROKE (BEAT-STROKE) is a cluster randomized controlled trial, testing whether an educational and implementation Neurocardiology tool can improve adherence to best practice recommendations for secondary stroke prevention of cardioembolic strokes, as defined by the WSO Systematic Review and Synthesis of Global Stroke Guidelines or more recent high-quality evidence published after the last stroke guidelines1
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with ischemic stroke or TIA of any etiology.
Disqualifiers
N/A
Trial design
Parallel
Treatments tested in this trial
Educational and implementation Neurocardiology tool
Other interventionSites in this arm will be provided with an educational and implementation Neurocardiology tool aiming to improve adherence to best practice recommendations for secondary stroke prevention of cardioembolic strokes, as defined by the WSO Systematic Review and Synthesis of Global Stroke Guidelines or more recent high-quality evidence published after the last stroke guidelines1.
No educational or implementation tool will be provided
Other interventionParticipants will be followed for up to 12 months. No educational or interventional tool will be provided to sites in this arm until the follow-up period has ended.
Treatment groups
Trial outcomes
Primary outcomes
Difference between the baseline and 6-month mean WSO BEAT Neurocardiology Score
Difference between the baseline and 6-month mean WSO BEAT Neurocardiology Score. The score for each patient will be calculated by adding the total points and dividing this number by the total ideal points for that patient, given that not all patients will qualify for the (embolic stroke of undetermined source (ESUS), PFO or AF points).
Secondary outcomes
Difference between the baseline and 6-month mean WSO BEAT Neurocardiology Score for each of the 5 pre-specified cathegories.
Difference between the baseline and 6-month mean WSO BEAT Neurocardiology Score for each of the 5 pre-specified categories: basic assessment, stroke-heart syndrome, ESUS workup, PFO in young patients, and AF management.
Long-term achievement of the primary outcome at 12 months.
Difference between the baseline and 12-month mean WSO BEAT Neurocardiology Score. The score for each patient will be calculated by adding the total points and dividing this number by the total ideal points for that patient, given that not all patients will qualify for the (embolic stroke of undetermined source (ESUS), PFO or AF points).
Other outcomes
Exploratory endpoint. Major adverse cardiovascular events (MACE) at 12 months
Major adverse cardiovascular events (MACE) at 12 months defined as the composite of the following events: * Recurrent ischemic stroke. * Acute coronary event. * Admission or Emergency Department visit for decompensated heart failure (HF), AF, or valvular heart disease. * New diagnosis of coronary artery disease. * Cardiovascular death.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Lead sponsor
W.L.Gore & Associates
Collaborator
Medtronic
Collaborator
This trial is not recruiting at the moment. You can still explore other options: